Drug Database · Clinicians

Tranexamic acid

Brands (127) Actranex, Hemostan, Hemanex…Show all
Actranex · Hemostan · Hemanex · Hemocare · Trenaxin · Cycloxid · Dostan · Exaclot · Hemoclot · Hemostap · Hemotrex · Hemoxane · Tranexamin · Traxan · Amptrex · Anclotic · Aneptil · ANEXA · Armatrax · Armaxenic · Betranex · Clotranex · Clottinex · Curaclot · Cyclotrax · Epitrax · Exzamixx · FERXAMIC · Furenex · Genex · Glotrek · Haemonav · Haemorex · Hemarife · Hematran · Hemitan · Hemobas · Hemoden · Hemofar · Hemofix · Hemoflaz · Hemosave · Hemosolv · Hemostar · Hemostat · Hemostiva · Hemotran · Hemotrax · Hemovee · Hemoxid · Hemoxin · KEXAMIC · Khrizemic · Kontranex · Mixtranz · Nexavell · Nexzatran · Pantrex · Pause 500 · Pillxamic · Premtexa · Ranesan · Ranex · Ranexid · Ranexstar · Raxami · Rexamic · Sitixamic · Suprehem · Tafixyl · Tanego · Tarnax · Tarnex · Tazojor · Texakind · Tracid · Trajex · Tralite · Tramacid · Tramed · Tramic-500 · Trance · Trancid-500 · Trane-West · Tranellen-PE100 · Tranesalv · Tranesaph · Tranesave · Tranex · Tranexa IV · Tranexagen · Tranexam · Tranexaprime · Tranexare · Tranexbest · Tranexell · Tranexfree · Tranexid · Tranexmed · Tranexsaph · TRANEXSETH · Tranext · Tranez · Tranhil · Tranicko · Traniject · Tranix · Tranmed · Tranova · Tranquafix · Transan · Transtat 500 · Trantran · Tranz · Tranzil · Traxozol · Trazuper · Trenaxid · Trenzamic · Trexabliss · Trifex · Triqox · Unotation · Vasocool · Xanil · Xed · Zetranex

US brand (reference label): Cyklokapron; not a Philippine-registered brand.

Antifibrinolytic Agent US FDA class
Antifibrinolytic (amino acid); Antifibrinolytic agent; and others PH FDA category

Rx · Prescription drug156 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 6e89a7d9-4da4-42aa-b7f8-c602c24eefe5, version date September 3, 2025 (Cyklokapron · Pfizer Laboratories Div Pfizer Inc). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • CYKLOKAPRON ® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE CYKLOKAPRON ® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. CYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. (1)

Contraindications

4 CONTRAINDICATIONS CYKLOKAPRON Injection is contraindicated:

  • As a neuraxial (i.e., intrathecal, epidural) injection [see Warnings and Precautions (5.1)].
  • In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in such patients.
  • In patients with active intravascular clotting [see Warnings and Precautions (5.2)].
  • In patients with hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions (5.4)].
  • As a neuraxial (i.e., intrathecal, epidural) injection. (4)
  • In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction. (4)
  • In patients with active intravascular clotting. (4)
  • In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients. (4)
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • Before Extraction: Administer 10 mg/kg actual body weight of CYKLOKAPRON intravenously with replacement therapy as a single‑dose. (2.1)
  • • After Extraction: Administer 10 mg/kg actual body weight of CYKLOKAPRON intravenously 3 to 4 times daily for 2 to 8 days. (2.1)
  • • Infuse undiluted solution no more than 1 mL/minute to avoid hypotension. (2.3)
  • • Reduce the dosage for patients with renal impairment. (2.2, 8.6)
2.1 Recommended Dosage

2.1 Recommended Dosage The recommended dose of CYKLOKAPRON is 10 mg/kg actual body weight administered as a single intravenous dose immediately before tooth extractions. Following tooth extraction, CYKLOKAPRON may be administered at a dose of 10 mg/kg actual body weight intravenously 3 to 4 times daily for 2 to 8 days.

2.2 Recommended Dosage for Patients With Varying Degrees of Renal Impairment

2.2 Recommended Dosage for Patients With Varying Degrees of Renal Impairment For patients with moderate to severe impaired renal function, the following dosages are recommended: Table 1. Recommended Dosage in Patients With Varying Degrees of Renal Impairment Dose reduction is recommended for all doses, both before and after tooth extraction.

Serum Creatinine (mg/dL) CYKLOKAPRON Dosage 1.36 mg/dL to 2.83 mg/dL 10 mg/kg intravenously twice daily 2.83 mg/dL to 5.66 mg/dL 10 mg/kg intravenously daily >5.66 mg/dL 10 mg/kg intravenously every 48 hours or 5 mg/kg intravenously every 24 hours

2.3 Preparation and Administration

2.3 Preparation and Administration CYKLOKAPRON is for intravenous administration only. CYKLOKAPRON can be administered undiluted or as a diluted solution.

  • Use aseptic technique to prepare CYKLOKAPRON.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. CYKLOKAPRON is a clear and colorless solution. Discard the vial if particulate matter is observed.
  • Calculate the dose (mg) based on the patient’s actual body weight and the total volume (mL) of CYKLOKAPRON solution required. If diluting CYKLOKAPRON, follow the instructions below:
  • From the diluent infusion bag, withdraw a volume equal to the volume of the CYKLOKAPRON solution required for the patient’s dose.
  • Withdraw the required volume of CYKLOKAPRON solution from the vial and dilute with a compatible diluent (see below) to make a final concentration of 10 mg/mL or 20 mg/mL. Discard any unused portion left in the vial. o For intravenous infusion, CYKLOKAPRON Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. o Heparin may be added to CYKLOKAPRON Injection. o CYKLOKAPRON Injection should NOT be mixed with blood. o The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin.
  • Gently invert the infusion bag to mix the diluted solution. DO NOT SHAKE.
  • If not used immediately, store the diluted CYKLOKAPRON infusion solution at room temperature 20ºC to 25°C (68ºF to 77°F) for up to 4 hours. Administration Infuse undiluted solution no more than 1 mL/minute to avoid hypotension [see Adverse Reactions (6.2)]. Administer the undiluted and diluted solutions intravenously according to Table 2. Table 2. Administration Rates for Undiluted and Diluted Solutions Undiluted solution Diluted solution Final concentration 100 mg/mL 10 mg/mL 20 mg/mL Administration rate 0.5 mL/minute (no more than 1 mL/minute) 5 mL/minute 2.5 mL/minute

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations, pharmacokinetics)

2.2 Recommended Dosage for Patients With Varying Degrees of Renal Impairment For patients with moderate to severe impaired renal function, the following dosages are recommended: Table 1. Recommended Dosage in Patients With Varying Degrees of Renal Impairment Dose reduction is recommended for all doses, both before and after tooth extraction. Serum Creatinine (mg/dL) CYKLOKAPRON Dosage 1.36 mg/dL to 2.83 mg/dL 10 mg/kg intravenously twice daily 2.83 mg/dL to 5.66 mg/dL 10 mg/kg intravenously daily >5.66 mg/dL 10 mg/kg intravenously every 48 hours or 5 mg/kg intravenously every 24 hours

8.6 Renal Impairment Reduce the dosage of CYKLOKAPRON in patients with renal impairment, based on the patient's serum creatinine [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].

Patients with Renal Impairment The blood levels of tranexamic acid are increased in patients with renal insufficiency. Urinary excretion following a single intravenous injection of tranexamic acid declines as renal function decreases. Following a single 10 mg/kg intravenous injection of tranexamic acid, the 24-hour urinary fractions of tranexamic acid with serum creatinine concentrations 1.4 – 2.8, 2.8 – 5.7, and greater than 5.7 mg/dL were 51, 39, and 19%, respectively.

The 24-hour tranexamic acid plasma concentrations for these patients demonstrated a direct relationship to the degree of renal impairment. Therefore, dose adjustment is needed in patients with renal impairment [see Dosage and Administration (2.2), Use in Specific Populations (8.6)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use There are limited data concerning the use of CYKLOKAPRON in pediatric patients with hemophilia who are undergoing tooth extraction. The limited data suggest that there are no significant pharmacokinetic differences between adults and pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical studies of CYKLOKAPRON did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].

Administration

2.3 Preparation and Administration CYKLOKAPRON is for intravenous administration only. CYKLOKAPRON can be administered undiluted or as a diluted solution. • Use aseptic technique to prepare CYKLOKAPRON. • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. CYKLOKAPRON is a clear and colorless solution. Discard the vial if particulate matter is observed. • Calculate the dose (mg) based on the patient’s actual body weight and the total volume (mL) of CYKLOKAPRON solution required. If diluting CYKLOKAPRON , follow the instructions below: • From the diluent infusion bag, withdraw a volume equal to the volume of the CYKLOKAPRON solution required for the patient’s dose. • Withdraw the required volume of CYKLOKAPRON solution from the vial and dilute with a compatible diluent (see below) to make a final concentration of 10 mg/mL or 20 mg/mL. Discard any unused portion left in the vial. o For intravenous infusion, CYKLOKAPRON Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. o Heparin may be added to CYKLOKAPRON Injection. o CYKLOKAPRON Injection should NOT be mixed with blood. o The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin. • Gently invert the infusion bag to mix the diluted solution. DO NOT SHAKE. • If not used immediately, store the diluted CYKLOKAPRON infusion solution at room temperature 20ºC to 25°C (68ºF to 77°F) for up to 4 hours. Administration Infuse undiluted solution no more than 1 mL/minute to avoid hypotension [see Adverse Reactions (6.2) ]. Administer the undiluted and diluted solutions intravenously according to Table 2. Table 2. Administration Rates for Undiluted and Diluted Solutions Undiluted solution Diluted solution Final concentration 100 mg/mL 10 mg/mL 20 mg/mL Administration rate 0.5 mL/minute (no more than 1 mL/minute) 5 mL/minute 2.5 mL/minute

US FDA label

Dosage forms

Philippines

  • ) solution for injection: 50 mg/mL (250 mg/5 mL, 100 mg/mL (250 mg/2.5 mL, 100 mg/mL (500 mg/5 mL, 100 mg/mL (500 mg/mL, 500 mg/5 mL (100 mg/mL
  • Solution for injection: 50 mg/mL, 100 mg/mL, 500 mg/5 mL
  • Capsule: 250 mg, 500 mg
  • Film-coated tablet: 500 mg
  • ) solution for intravenous injection: 100 mg/mL (500 mg/5 mL
  • ) solution fo injection: 100 mg/mL (500 mg/mL
  • ) solution for injection i.v: 50 mg/mL (250 mg/50 mL
  • ) solution for intravenous: 500 mg/5 mL (100 mg/mL
  • )solution for injection: 100 mg/mL (500 mg/5 mL
  • Mg/ml solution for injection: 100 mg/mL

and 2 more forms; see the products table.

Registered products in the Philippines

156 products registered with the Food and Drug Administration (FDA) Philippines list Tranexamic acid as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products156
Philippine FDA-registered products for Tranexamic acid
Package insert
ActranexTranexamic Acid
100 mg/mL (500 mg/5mL) Solution for Intravenous InjectionUSP Type 1 Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
The Cathay Drug Co., Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-5237-01
Apr 7, 2027
ActranexTranexamic acid
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
The Cathay Drug Co., Inc.Importer: AMB HK Enterprises Inc.
DRP-12770-01
Oct 6, 2027
ActranexTranexamic Acid
500 mg/5 mL (100 mg/mL) Solution for InjectionLow Borosilicate Glass Ampoule x 5mL in PVC tray (Box of 5's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
The Cathay Drug Co., Inc.
DR-XY48398
Oct 4, 2027
ActranexTranexamic Acid
500mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-12770
Oct 6, 2027
AmptrexTranexamic Acid
50 mg/mL Solution for Injection (I.M/I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 10's)
Rx
—
Steinbach Products, Inc.
DRP-4093
Nov 20, 2027
AncloticTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Suhitas Pharmaceuticals Inc.
DRP-5237
Apr 7, 2027
AneptilTranexamic Acid
500mg/5mL Solution for Injection
Rx
—
Importer: West Wing Pharma Sales Inc.
DRP-3418
Dec 6, 2026
ANEXATranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (as net content) in Plastic Tray (Box of 5’s)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC.
DRP-8687-01
May 20, 2029
ArmatraxTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Colorless Glass Ampoule x 5 mL (Box of 10's)
Rx
Union Korea Pharm Co., LtdKorea
Importer: H & B Pharma International Inc.
DRP-10924
Dec 17, 2026
ArmaxenicTranexamic Acid
50mg/mL (250mg/5mL) Solution For Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in plastic tray x 10's (Box of 10's)
Rx
Union Korea Pharm Co., LtdKorea
H & B Pharma International Inc.
FDA-0592706
Jun 6, 2028
BetranexTranexamic Acid
500 mg/5 mL Solution for Injection (I.M./I.V.)
Rx
Alina Combine Pharmaceutical (Pvt.) Ltd.
—
DRP-3418-01
Dec 6, 2026
ClotranexTranexamic Acid
100 mg/mL Solution for Injection (IV)10 mL USP Type I clear glass ampoule (Box of 1's)
Rx
Gland Pharma LimitedIndia
Pharma-Surrey International, Inc.
DRP-14862
Jan 25, 2029
ClottinexTranexamic Acid
500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-721
Oct 5, 2031
CuraclotTranexamic Acid
500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 100's)
Rx
Healer's Lab. Unit IIIndia
Curasave PharmaImporter: Pharmakon Biotec Inc.
DRP-5424-01
Aug 5, 2029
CyclotraxTranexamic Acid
100 mg/mL Solution for Injection (I.M./I.V.)Clear and Colorless Glass Ampoule x 5mL (Box of 10's)
Rx
Shin Poong Pharmaceutical Co., LtdRepublic of Korea
Phil. Pharmawealth, Inc.
DR-XY23884
Feb 20, 2028
CycloxidTranexamic Acid
100 mg/mL Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Box of 5’s)
Rx
Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China
Global PharmatradeTrader: Mecechem (Wuxi) CO., Ltd.
DR-XY45004
Jan 22, 2031
CycloxidTranexamic Acid
50 mg/mL (250 mg/50 mL) Solution For Injection I.VLow borosilicate glass ampoule x 5 mL (Box of 5's)
Rx
Reyoung Pharmaceutical Co., Limited.China
Global Pharmatrade
DRP-19122
Oct 29, 2031
DostanTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Heltker A.G. CorporationImporter: Ambica International Corporation
DRP-5172-07
Feb 13, 2029
DostanTranexamic Acid
500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Heltker A.G. Corporation
DR-XY30225
Nov 5, 2029
EpitraxTranexamic Acid
100mg/mL Solution for Injection (IV)Type I Clear Glass Ampoule x 5mL (Box of 5' and 10's)
Rx
Scott-Edil Pharmacia LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-14765-03
Dec 29, 2028
ExaclotTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)5 mL USP Type I Clear, Colorless Glass Ampoule (Box of 10's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-9087-03
Feb 19, 2029
ExaclotTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)5 mL USP Type I Clear, Colorless Glass Ampoule (Box of 10's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-9087-04
Feb 19, 2029
ExzamixxTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I clear glass ampoule with tray x 5 mL (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Ambica International CorporationImporter: Diafarm Inc.
DRP-11560-01
Mar 30, 2037
FERXAMICTranexamic Acid
500 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Bulacan
Ferma Drug Enterprises
DRP-4204-06
Feb 8, 2028
FurenexTranexamic Acid
500 mg/5mL (100 mg/mL) Solution For Injection (Im/Iv)Clear colorless glass ampoule x 5 mL (Box of 5's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Euro-Care Products Philippines
DRP-15310
Nov 4, 2031
GenexTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in PVC plastic tray (Box of 5's)
Rx
Farbe Firma Pvt. LtdIndia
Genzen Pharmaceutical TradingImporter: AMB HK Enterprises Inc.
DRP-13797-02
May 2, 2028
GlotrekTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
AGLOBAL CARE, INC.
DRP-8687
May 20, 2029
HaemonavTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's)
Rx
Unijules Life Sciences LimitedIndia
JN Carlo Pharmaceuticals DistributorImporter: Aglobal Care, Inc.
DRP-8687-07
May 20, 2029
HaemorexTranexamic Acid
500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
New Myrex Laboratories, Inc.Philippines
—
DRP-2328
Mar 4, 2031
HemanexTranexamic Acid
100 mg/mL (500 mg/mL) Solution fo Injection (IM/IV)USP Type I Clear Glass Ampoule in a PVC Tray x 5 mL (Box of 5's)
Rx
Amherst Parenterals, Inc.Philippines
Trader: Unilab, Inc.
DR-XY43305
Mar 13, 2029
HemanexTranexamic Acid
500 mg CapsuleAluminum Blister Pack x 10's (Box of 100's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc
DRP-11169
Feb 9, 2027
HemanexTranexamic Acid
500 mg CapsuleBlister Pack x 10's Box of 100's
Rx
Amherst Laboratories, Inc.Philippines
UNILAB, Inc.
DRP-2847-02
May 24, 2027
HemarifeTranexamic Acid
100 mg/mL Solution For Injection (IV)Clear glass ampoule x 5 mL in plastic tray x 10's
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DRP-14021
Jun 6, 2028
HematranTranexamic Acid
100 mg/mL Solution for Injection (IV)Type I clear glass ampoule x 5 mL (Box of 5’s & 10’s)
Rx
Scott-Edil Pharmacia LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-14765-01
Dec 29, 2028
HemitanTranexamic acid
500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17134
Oct 10, 2031
HemobasTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)5 mL USP Type I Clear, Colorless Glass Ampoule (Box of 10's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
RAQUEL-ABBAS PHARMACEUTICALS & GENERAL MERCHANDISE
DRP-9087
Feb 19, 2029
HemocareTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5’s)
Rx
Unijules Life Sciences LimitedIndia
Euro-Care Products PhilippinesImporter: Aglobal Care, Inc.
DRP-8687-04
May 20, 2029
HemocareTranexamic Acid
500 mg/5 mL (100 mg/mL) Solution for Injection (IM/IV)5 mL clear colorless glass ampoule (Box of 5's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Asianmeds, Inc.Importer: Euro-Care Products Philippines
DRP-15310-03
Jun 18, 2029
HemocareTranexamic Acid
500mg/5mL Solution for Injection
Rx
Alina Combine Pharmaceutical (Pvt.) Ltd.
—
DRP-3418-05
Dec 6, 2026
HemoclotTranexamic Acid
250 mg CapsuleBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Bulacan
Solvang Pharmaceuticals, Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-4058-01
Oct 5, 2036
HemoclotTranexamic Acid
500 mg CapsuleAlu/Clear PVDC Blister Pack of 10's Box of 100's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-10014
Jul 19, 2027
HemodenTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in PVC plastic tray (Box of 5's)
Rx
Farbe FirmaIndia
Cyden Medicale Trading Inc.Importer: AMB HK Enteprises Inc.
DRP-13797-01
May 2, 2028
HemofarTranexamic Acid
500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 100's)
Rx
Healer's Lab. Unit IIIndia
Pharmakon Biotec Inc.
DRP-5424
Aug 5, 2029
HemofixTranexamic Acid
100 mg / mL (500 mg / 5 mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net content) in a plastic tray (Box of 5's)
Rx
Skymap Healthcare Pvt. Ltd.India
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-15874-02
Sep 25, 2029
HemoflazTranexamic Acid
100 mg/mL Solution for Injection (IV)Type I clear glass ampoule x 5 mL (Box of 5's and 10's) `
Rx
Scott-Edil Pharmacia LimitedIndia
Despina Pharma Inc.
DRP-14765
Dec 29, 2028
HemosaveTranexamic Acid
500 mg / 5 mL (100 mg / mL) Solution for Injection (IV)5 mL USP Type I Clear Ampoule (Box of 5's and 10's)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc.
DRP-15221-02
Jun 18, 2029
HemosolvTranexamic Acid
500 mg CapsuleAlu/Clear PVDC Blister Pack of 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Dr. Zen's Research, Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-10014-01
Jul 19, 2027
HemostanTranexamic acid
100 mg/mL (250 mg/2.5 mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 2.5 mL (Box of 5's)
Rx
Amherst Parenterals, Inc.Philippines
Trader: UNILAB, INC.
DR-4759
Sep 16, 2027
HEMOSTANTranexamic acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 5 mL Box of 5's
Rx
Amherst Parenterals, Inc.Philippines
Trader: UNILAB, INC.
DRP-8449
Sep 16, 2027
HemostanTranexamic Acid
250 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR‐5167
Oct 24, 2027
HemostanTranexamic Acid
500 mg CapsuleBlister Pack x 10's (Box of 100's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DRP-2847
May 24, 2027
HemostapTranexamic Acid
250 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-4271
Feb 26, 2028
HemostapTranexamic Acid
500 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-4204
Feb 8, 2028
HemostarTranexamic Acid
500 mg CapsulePVC Blister Pack x 10's (Box of 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Starpharm, Inc.
DRP-4204-04
Feb 8, 2028
HemostatTranexamic Acid
500mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 20's)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading, Inc.
DR-XY41545
Jan 10, 2028
HemostivaTranexamic Acid
100mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5 mL in PVC Tray (Box of 5’s and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd..China
Philrx Pharma Inc.
DRP-18919
Sep 30, 2031
HemotranTranexamic Acid
500 mg CapsuleBlister Pack x 10's (Box of 100's)
Rx
LLOYD LABORATORIES, INC.Philippines
ALTOMED PHARMACEUTICALS, INC.Trader: FORAMEN PRODUCTS CORPORATION
DRP-718-03
Sep 22, 2031
HemotraxTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net content) in a plastic tray (Box of 5's)
Rx
Skymap Healthcare Pvt. Ltd.India
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-15874-01
Sep 25, 2029
HemotrexTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (as net content) in Plastic Tray (Box of 5’s)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
NUTRAMEDICA INCImporter: AGLOBAL CARE, INC.
DRP-8687-02
May 20, 2029
HemotrexTranexamic Acid
500 mg CapsuleBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Nutramedica Inc.Trader: Foramen Products Corporation
DRP-718
Oct 2, 2031
HemoveeTranexamic Acid
100 mg/mL (500mg/5mL) Solution for Injection (I.M./I.V.)5 mL USP Type 1 Low Borosilicate Glass Ampoule (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Euro-Care Products Philippines.
DRP-15351
Jul 3, 2029
HemoxaneTranexamic Acid
100 mg/mL Solution for injection (IV)USP Type I Clear Glass Ampoule x 5 mL (Box of 5's)
Rx
Mercury Laboratories Ltd.India
Phil Pharmawealth, Inc.
DR-XY44554
May 14, 2027
HemoxaneTranexamic Acid
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 50's)
Rx
Mercury Laboratories Ltd.India
Phil Pharmawealth Inc.
DR-XY38149
Jun 5, 2030
HemoxidTranexamic Acid
500 mg CapsuleBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Foramen Products Corporation
DRP-718-01
Sep 1, 2031
HemoxinTranexamic Acid
500 mg CapsuleAlu/Clear PVC Blister pack x 10's (Box of 100's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-5833
Mar 15, 2030
KEXAMICTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (as net content) in Plastic Tray (Box of 5’s)
Rx
UNIJULES LIFE SCIENCES LIMITEDIndia
PHARMA KING DISTRIBUTORImporter: AGLOBAL CARE, INC.
DRP-8687-03
May 20, 2029
KhrizemicTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5 mL (net content) USP Type I clear and colorless glass ampoule x 5 ampoules in a plastic tray (box of 25 ampoules)
Rx
Skymap Healthcare Pvt. Ltd.India
Khriz Pharma Trading, Inc.
DR-XY49092
May 24, 2029
KontranexTranexamic Acid
500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Konzept Convenience and Drug Store Corp.
DRP-4204-03
Feb 8, 2028
MixtranzTranexamic Acid
100 mg/mL (500 mg/ 5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I clear glass ampoule with tray x 5 mL (Box of 10’s)
Rx
Makcur Laboratories LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Diafarm Inc.
DRP-11560-02
Mar 30, 2027
NexavellTranexamic acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 5 mL (Box of 5's)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY43251
Dec 10, 2028
NexzatranTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I clear glass ampoule with tray x 5 mL (Box of 10’s)
Rx
Makcur Laboratories LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Diafarm Inc.
DRP-11560-03
Mar 30, 2037
NoneTranexamic Acid
100 mg /mL (500 mg / 5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s)
Rx
East African (India) OverseasIndia
Reta DrugImporter: Ambica International Corporation
DRP-13005-02
Nov 16, 2027
NoneTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear glass ampoule x 5 mL in Alu/PVC blister (Box of 4’s)
Rx
Mankind Pharma Limited (Unit-I)India
Reta DrugImporter: Ambica International Corporation
DRP-14087-01
Jun 20, 2028
NoneTranexamic acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 5 mL Box of 5's
Rx
Amherst Parenterals, Inc.Philippines
RITEMED PHILS., INC.Trader: UNILAB, INC.
DRP-8449-01
Sep 16, 2027
NoneTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Scheeling, Inc.Importer: Ambica International Corporation
DRP-5172-02
Feb 13, 2029
NoneTranexamic Acid
500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Drugmaker's Laboratories IncPhilippines
TGP Pharma Inc.
DRP-5833-01
Mar 15, 2030
PantrexTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I Glass Ampoule x 5 mL (Box of 10's)
Rx
Ying Yuan Chemical Pharmaceutical Co., Ltd.Taiwan
Pan-Ject Pharmaceuticals Corp.
DRP-626
Mar 21, 2030
Pause 500Tranexamic Acid.
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10 Tablets (Box of 30's)
Rx
Emcure Pharmaceuticals Ltd.India
Emcure Pharma Philippines Inc.
DR-XY49072
May 7, 2029
PillxamicTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s)
Rx
East African (India) OverseasIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-13005-03
Nov 16, 2027
PremtexaTranexamic Acid
100 mg / mL (500 mg/5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s)
Rx
East African (India) OverseasIndia
Premier Pharmaceuticals Marketing Corp.Importer: Ambica International Corporation
DRP-13005-04
Nov 16, 2027
RanesanTranexamic Acid
100 mg / mL (500 mg / 5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's)
Rx
Unijules Life Sciences LimitedIndia
Sannovex Pharmaceutical DistributorImporter: Aglobal Care, Inc.
DRP-8687-05
May 20, 2029
RanexTranexamic Acid
100 mg/mL Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (Box of 5 ampoules in plastic tray)
Rx
Steril-Gene Life Sciences (P) Ltd.India
Aglobal Care, Inc.
DRP-11981
May 25, 2027
RanexidTranexamic Acid
100mg/mL Solution for Injection (IV)Clear Glass Ampoule x 5mL (Box of 10's)
Rx
Yung Shin Pharm. Ind. Co., Ltd- Taichung Youth FactoryChina
Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc.
DRP-1043-01
Nov 13, 2027
RanexstarTranexamic Acid
100 mg/mL (500 mg/5mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net content) in a plastic tray (Box of 5's)
Rx
Skymap Healthcare Pvt. Ltd.India
Twostar Pharmaceutical TradingImporter: Medinova Pharmaceutical Inc.
DRP-15874-03
Sep 25, 2029
RaxamiTranexamic Acid
100 mg/Ml Solution For InjectionAmber glass ampoule with blue band x 5 mL (Box of 5 ampoules in a tray)
Rx
SANJAR PHARMA LLPIndia
Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-14194
Jul 17, 2028
RexamicTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I clear transparent ampoule in a carton x 5 mL (box of 5’s)
Rx
Hiral Labs LimitedIndia
Bellus Life Solutions, Inc.
DRP-18052
Apr 30, 2031
SitixamicTranexamic Acid
500 mg/5 mL Solution for Injection (I.V.)Low Borosilicate Glass Ampoules in a Plastic Tray x 5 mL x 10's (Box of 10's)
Rx
Tianjin Kingyork Group Hubei Tianyao Pharmaceutical Co., Ltd.China
Sahar International Trading Inc.Trader: ZLF Pharmaceutical Limited
DR-XY49124
Jul 5, 2029
SuprehemTranexamic Acid
500 mg CapsuleAlu/PVC Blister Pack x 10’s Box of 100’s
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DR-XY41289
Oct 2, 2027
TafixylTranexamic Acid
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 20's)
Rx
Labiana Pharmaceuticals, S.L.USpain
Qualicare Pharma, Inc.Trader: Pharma Bavaria International GmbH
DR-XY48117
Jun 17, 2027
TanegoTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Glass Ampoule x 5 mL in White Hips Plastic Tray (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Importer: Afree Pharmaceutical Distribution Corp.
DRP-12666
Sep 22, 2027
TarnaxTranexamic Acid
100 mg/mL Solution for Injection (I.M./I.V.)5 mL USP Type I clear glass tray (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Despina Pharma Inc
DRP-15630
Aug 13, 2029
TarnexTranexamic Acid
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Inc.
DR-XY35552
May 30, 2029
TazojorTranexamic Acid
100 mg/mL (500mg/5 mL) Solution for Injection (I.V)USP Type I clear colourless glass ampoule x 5 mL (Box of 5's)
Rx
East African (India) OverseasIndia
Ambica International Corporation
DRP-13006
Nov 16, 2027
TexakindTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear transparent Glass Ampoule with colored collar ring packed in an Alu/PVC Blister x 5 mL
Rx
Mankind Pharma Limited (Unit-I)India
Ambica International Corporation
DRP-14087
Jun 20, 2028
TracidTranexamic acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I Clear glass ampoule x 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Applied Pharmaceutical Distribution Inc.
DRP-15035
Mar 22, 2029
TrajexTranexamic Acid
100 mg/mL Solution For Injection (IM/IV)Type I Clear Glass vial Ampoule x 2.5 mL and 5 mL (Box of 5's and 10's)
Rx
Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China
Raquel Abbas Pharma Inc.
DRP-18950
Oct 6, 2031
TraliteTranexamic Acid
500 mg Film-Coated TabletAlu/PVC blister pack x 10’s (Box of 30’s)
Rx
Globela Pharma Private LimitedIndia
Fspc Pharmaceuticals Inc.Importer: Amb Hk Enterprises Inc.
DRP-12770-02
Oct 6, 2027
TramacidTranexamic Acid
500 mg CapsulePVC Blister Pack x 10's (Box of 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-4204-01
Feb 8, 2028
TramedTranexamic Acid
500 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's; Box of 100's)
Rx
Acme Formulation Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-10306
Sep 9, 2031
Tramic-500Tranexamic Acid
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
West Coast Pharmaceutical Works Ltd.India
Ambica International Corporation
DRP-6193
Jun 23, 2030
TranceTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for injection (IV)USP TYpe I Clear glass Ampoule x 5 mL (Box of 5's)
Rx
Celon Laboratories Private LimitedIndia
Meedpharma Medical Supplies & Equipment DistributorImporter: I.E Medica, Inc.
DRP-4153
Dec 18, 2030
Trancid-500Tranexamic Acid
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-18217
Jun 2, 2031
Trane-WestTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Central West Medicale Inc.Importer: Ambica International Corporation
DRP-5172-05
Feb 13, 2029
Tranellen-PE100Tranexamic Acid
100mg/mL Solution for Injection (IM/IV)5 mL and 2.5 mL USP Type I amber glass ampoule (Box of 5’s and 10’s)
Rx
Penam Biosciences Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-18594
Aug 4, 2031
TranesalvTranexamic Acid
500mg/5mL Solution for Injection
Rx
Alina Combine Pharmaceutical (Pvt.) Ltd.
—
DRP-3418-02
Dec 6, 2026
TranesaphTranexamic Acid
100mg/mL Solution For Injection (IV)USP Type I Flint glass ampoule x 5 mL (Box of 10 ampoules in PVC tray; Box of 5 ampoules in PVC tray); USP Type I Flint glass ampoule x 2.5 mL (Box of 10 ampoules in PVC tray; Box of 5 ampoules in PVC tray)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifescience Pvt. Ltd.
DRP-11329
Mar 3, 2027
TranesaveTranexamic Acid
100 mg / mL (500 mg /5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s)
Rx
East African (India) OverseasIndia
Curasave Ve PharmaImporter: Ambica International Corporation
DRP-13005-01
Nov 16, 2027
TranexTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's)
Rx
Unijules Life Sciences LimitedIndia
Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc.
DRP-8687-06
May 20, 2029
Tranexa IVTranexamic Acid
100 mg/mL Solution for Injection (IV)USP Type I amber Glass ampoule x 5mL (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Pharmakon Biotec Inc.
DRP-11331
Mar 3, 2027
TranexagenTranexamic Acid
250 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-4271-01
Feb 26, 2028
TranexamTranexamic Acid
100 mg / mL (500 mg / 5 mL) Solution for Injection (IV)Type I Colorless Glass Ampoule x 5 mL (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Central West Medicale Inc.Importer: H&B Pharma International Inc.
DRP-10924-01
Dec 17, 2026
TranexaminTranexamic Acid
100 mg / mL (500 mg/ 5 mL) Solution for Injection (IM/IV)USP Type I Clear and Colorless Glass Ampoule x 5 mL (Box of 10's)
Rx
Daihan Pharm. Co., Ltd.Republic of Korea
Largen Med Inc
DRP-15703
Mar 5, 2028
TranexaminTranexamic Acid
100 mg/ mL (500 mg/ 5 mL) Solution for Injection (IM/IV)USP Type I Clear and Colorless Glass Ampoule x 5 mL Box of 10's
Rx
Daihan Pharm. Co., Ltd.Republic of Korea
Largen Med Inc.
DR-XY46273
Mar 5, 2028
TranexaprimeTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-5172-04
Feb 13, 2029
TranexareTranexamic Acid
500 mg/5 mL (100 mg/mL) Solution for Injection (IV)5 mL USP Type I Clear Glass Ampoule (Box of 5's)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Neo Care Philippines, Inc.Importer: Accesspoint International Trading Inc.
DRP-15221-01
Jun 18, 2029
TranexbestTranexamic Acid
500 mg/5 mL (100 mg/mL) Solution for Injection (IM/IV)5 mL clear colorless glass ampoule (Box of 5's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Best ClearImporter: Euro-Care Products Philippines
DRP-15310-01
Jun 18, 2029
TranexellTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Tamiga Pharmaceuticals SupplyImporter: Ambica International Corporation
DRP-5172-06
Feb 13, 2029
TranexfreeTranexamic Acid
100mg/mL (500mg/5mL) Solution for Injection (IV)Type I Clear Glass Ampoule x 5 mL in White Hips Plastic tray (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Bliss Pharma Distribution And Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-12666-01
Sep 22, 2027
TranexidTranexamic Acid
500 mg/5 mL Solution for Injection (I.M. / I.V.)USP Type I Clear Glass Ampoule x 5mL (Box of 5's)
Rx
Alina Combine Pharmaceutical (Pvt.) Ltd.Pakistan
Seahorse Industries, Inc.Importer: West Wing Pharma Sales Inc.
DRP-3418-04
Dec 6, 2026
TranexmedTranexamic Acid
500 mg/5 mL (100 mg/mL) Solution for Injection (IM/IV)5 mL clear colorless glass ampoule (Box of 5's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Blue Medceuticals Marketing Corp.Importer: Euro-Care Products Philippines
DRP-15310-02
Jun 18, 2029
TranexsaphTranexamic Acid
500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-13371
Feb 8, 2028
TRANEXSETHTranexamic Acid
Capsule 500 mgAlu/Clear PVC Blister Pack x 10’s (Box of 100's)
Rx
Genom Biotech Pvt. Ltd.India
999-SETH PHARMACEUTICAL INC.Importer: Nelpa Lifesciences, Inc.
DRP-14574-01
May 19, 2030
TranextTranexamic Acid
500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-4534
Jul 23, 2028
TranezTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule x 5 mL (Box of 10 ampoules x 5mL in plastic tray)
Rx
Makcur Laboratories LimitedIndia
Seapharma International, IncTrader: Yeluri Formulations Pvt. Ltd.
DRP-13959
Sep 24, 2029
TranhilTranexamic Acid.
100 mg/mL (500 mg/5 mL) Solution for Injection (I.M./I.V.)5 mL Type I clear glass ampoule (Box of 10's)
Rx
Makcur Laboratories Limited.India
Hillcross Prime, Inc.
DRP-12009
Sep 24, 2029
TranickoTranexamic Acid
100 mg/mL Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5mL in plastic tray x 5's (Box of 5's)
Rx
Pharmax India Private LimitedIndia
Wellchem Pharmaceutical Products
DRP-16705
Jun 24, 2030
TranijectTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Meedpharma Medical Supplies & Equipment DistributorImporter: Ambica International Corporation
DRP-5172-03
Feb 20, 2029
TranixTranexamic Acid
100 mg/mL (500 mg/5 mL)Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL Box of 5's
Rx
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E MEDICA INC.
DRP-4153-02
Sep 29, 2031
TranmedTranexamic Acid
100mg/mL (500mg/5mL) Solution For Injection (IM/IV)5mL Type I clear ampoule (Box of 5's)
Rx
Medchem International LimitedIndia
Pharma-Surrey International, Inc.
DR-XY40235
Nov 17, 2026Past listed date
TranovaTranexamic acid.
500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 10's & 100's)
Rx
Saga Lifesciences LimitedIndia
Medinova Pharmaceutical Inc.
DRP-15289
Jun 10, 2029
TranquafixTranexamic Acid
500 mg CapsuleAlu / PVC Blister Pack x 10's (Box of 10's & 100's)
Rx
Saga Lifesciences LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-15289-01
Jun 10, 2029
TransanTranexamic Acid
100 mg/mL Solution For Injection (IV)5 mL USP Type-I Flint Glass Ampoule In A Plastic Tray (Box of 5's)
Rx
Gufic Biosciences Ltd.India
SRS Pharmaceuticals Phils Inc.
DR-XY46073
Oct 6, 2027
Transtat 500Tranexamic Acid
500 mg Film-Coated TabletAlu/Clear PVC/PVdC Blister Pack x 10's (Box of 60's); Alu/Clear PVC/PVdC Blister Pack x 4's (Physician's Sample)
Rx
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY46215
Jan 26, 2030
TrantranTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5mL Clear Glass Ampoule in PVC Tray (Box of 5's)
Rx
Pharmax India Private LimitedIndia
Ambica International Corporation.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd.
DRP-13016
Nov 17, 2027
TranzTranexamic Acid
500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 100's)
Rx
Healer's Lab. Unit IIIndia
One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc.
DRP-5424-02
Aug 5, 2029
TranzilTranexamic Acid
500 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 100’s)
Rx
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-3208
Aug 25, 2031
TraxanTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation
DRP-5172-01
Feb 13, 2029
TraxanTranexamic Acid
500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Bulacan
Multicare Pharmaceuticals Philippines, Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-721-03
Oct 5, 2031
TraxozolTranexamic Acid
100 mg / mL mg/mL Solution for Injection (IV)USP Type 1 Amber Glass Ampoule x 5 mL (Box of 5's in a PVC tray)
Rx
Kamla Lifesciences Ltd.India
Ambica International CorporationTrader: Omnicals Pharma Private Limited
DRP-18472
Jul 23, 2031
TrazuperTranexamic Acid
100 mg/mL (500mg/5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5's)
Rx
East African (India) OverseasIndia
Ambica International Corporation
DRP-13005
Nov 16, 2027
TrenaxidTranexamic Acid
100 mg / ml Solution for Injection (IV)Type I clear glass ampoule x 5 ml (Box of 5’s and 10's)
Rx
Scott-Edil Pharmacia LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-14765-02
Dec 29, 2028
TrenaxinTranexamic Acid
100mg/mL Solution for Injection (IV)Clear Glass Ampoule x 5mL Box of 10's
Rx
Yung Shin Pharm., Ind. Co., Ltd.- Taichung Youth FactoryR.O.C
Yung Shin (Philippines), Inc.
DRP-1043
Nov 13, 2027
TrenaxinTranexamic Acid
250mg CapsuleAlu/PVC Blister Pack x 10's Box of 100's
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DR-XY35553
Mar 5, 2031
TrenaxinTranexamic acid
500 mg/5 mL (100 mg/mL) Solution for Intravenous5 mL-net content Type I clear glass ampoule (Box of 10's).
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DRP-15536
Jul 31, 2029
TrenzamicTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I Clear Glass Ampoule with Tray x 5 mL (Box of 10’s)
Rx
Makcur Laboratories LimitedIndia
Diafarm Inc.
DRP-11560
Mar 30, 2032
TrexablissTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Glass Ampoule x 5 mL in White Hips Plastic Tray (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-12666-02
Sep 22, 2027
TrifexTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's)
Rx
Gufic Biosciences LimitedIndia
Ambica International Corporation
DRP-5172
Feb 13, 2029
TriqoxTranexamic Acid
100 mg/mL Solution For Injection (IV/IM)USP Type I Clear Glass Ampoule x 5 mL (Box of 10 ampoules in PVC tray)
Rx
Indus Pharma (Pvt.) Ltd.Pakistan
AMEDIQO PHILS., INC.Importer: One Dexcel Pharma Inc.
DRP-11171-01
Feb 8, 2027
UnbrandedTranexamic Acid
100 mg/mL Solution for Intravenous InjectionUSP Type I clear glass ampoule x 5 mL in plastic tray (Box of 5’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India
Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Limited
DRP-11399
Mar 8, 2032
UnotationTranexamic Acid
500 mg/5 mL (100 mg/mL) Solution for Injection (IV)5 mL USP Type I Clear and Colorless Glass Ampoule in PVC Tray (Box of 5's)
Rx
Akums Drugs & Pharmaceuticals Ltd (Plant III - Injectables)India
SMHP Pharmaceuticals IncorporatedTrader: Unosource Pharma Ltd
DRP-10574
Oct 18, 2031
VasocoolTranexamic Acid
100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in PVC plastic tray (Box of 5's)
Rx
Farbe FirmaIndia
AMB HK Enterprises Inc.
DRP-13797
May 2, 2028
XanilTranexamic Acid
100 mg/mL Solution for Injection (IV)Low Borosilicate Glass Ampoule x 5 mL (Box of 5's and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-17004
Sep 4, 2030
XedTranexamic Acid
100 mg/mL Solution for Injection (IV/IM)USP Type I Clear Glass Ampoule x 5 mL (Box of 10 ampoules in PVC tray)
Rx
Indus Pharma (Pvt.) Ltd.Pakistan
One Dexcel Pharma Inc.
DRP-11171
Oct 18, 2028
ZetranexTranexamic Acid
500 mg CapsulePVC Blister Pack x 10's (Box of 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Hale Medipoint Corp.
DRP-4204-05
Feb 8, 2028
(no brand name)Tranexamic Acid
100 mg/mL (500 mg/mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net conten) in a plastic tray (Box of 5's)
Rx
Skymap Healthcare Pvt. Ltd.India
Medinova Pharmacuetical Inc.
DRP-15874
Sep 25, 2029
(no brand name)Tranexamic Acid
100 mg/mL Solution for Injection (I.V.)USP Type I Flint Glass Ampoule with Yellow Dot OPC x 5 mL (Box of 5's)
Rx
Samrudh Pharmaceuticals Pvt. Ltd.India
I.E. Medica, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-15667
Aug 16, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: 1,000 mg/10 mL (100 mg/mL) clear and colorless solution in single-dose ampules Injection: 1,000 mg/10 mL (100 mg/mL) clear and colorless solution in single-dose vials • Injection: 1,000 mg/10 mL (100 mg/mL) in single-dose ampules (3) • Injection: 1,000 mg/10 mL (100 mg/mL) in single-dose vials (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • Risk of Thrombosis with Concomitant Use of Factor IX: Avoid concomitant use. (5.2)
  • • Seizures: Inadvertent injection into neuraxial system may result in seizures. (5.3)
  • • Hypersensitivity Reactions: In case of severe reaction, discontinue use and seek immediate medical attention. (5.4)
  • • Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur. (5.5)
  • • Dizziness: Advise patients not to drive if dizziness occurs. (5.6)
5.1 Risk of Medication Errors Due to Incorrect Route of Administration

5.1 Risk of Medication Errors Due to Incorrect Route of Administration CYKLOKAPRON is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when CYKLOKAPRON was inadvertently administered via the neuraxial route. Confirm the correct route of administration for CYKLOKAPRON and avoid confusion with other injectable solutions that might be administered at the same time as CYKLOKAPRON.

Clearly label syringes containing CYKLOKAPRON with the intravenous route of administration.

5.2 Thromboembolic Risk

5.2 Thromboembolic Risk CYKLOKAPRON is contraindicated in patients with active intravascular clotting. Tranexamic acid is an antifibrinolytic and may increase the risk of thromboembolic events. Venous and arterial thrombosis or thromboembolism has been reported in patients treated with CYKLOKAPRON. Avoid concomitant use of CYKLOKAPRON and medical products that are pro-thrombotic, as the risk of thrombosis may be increased.

These medications include but are not limited to, Factor IX Complex concentrates, Anti-inhibitor Coagulant concentrates, and hormonal contraceptives [see Drug Interactions (7.1), Use in Specific Populations (8.3)].

5.3 Seizures

5.3 Seizures CYKLOKAPRON may cause seizures, including focal and generalized seizures. The most common setting for tranexamic acid-induced seizures has been during cardiovascular surgery (a setting in which CYKLOKAPRON is not FDA‑approved and which uses doses of up to 10‑fold higher than the recommended human dose and in patients inadvertently given tranexamic acid via the neuraxial route).

CYKLOKAPRON is contraindicated for neuraxial administration (i.e., epidural, intrathecal). Consider dose reduction during surgery and dose adjustments for patients with clinical conditions such as renal dysfunction. Closely monitor the patient during surgery. Consider electroencephalogram (EEG) monitoring for patients with history of seizures or who experience myoclonic movements, twitching, or show evidence of focal seizures.

Discontinue CYKLOKAPRON if seizures occur.

5.4 Hypersensitivity Reactions

5.4 Hypersensitivity Reactions Cases of hypersensitivity reactions, including anaphylactic reactions, have occurred with use of intravenous tranexamic acid. Discontinue treatment with CYKLOKAPRON if serious reaction occurs, provide appropriate medical management, and do not restart treatment. CYKLOKAPRON is contraindicated in patients with a history of hypersensitivity to tranexamic acid.

5.5 Visual Disturbances

5.5 Visual Disturbances Although not seen in humans, focal areas of retinal degeneration have been observed in cats and dogs following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (1.6 to 22 times the recommended usual human dose based on body surface area) from 6 days to 1 year. No retinal changes have been observed in eye examinations of patients treated with tranexamic acid for up to 8 years.

Patients expected to be treated for greater than 3 months may consider ophthalmic monitoring including visual acuity and optical coherence tomography at regular intervals. Discontinue CYKLOKAPRON if changes in ophthalmological examination occurs.

5.6 Dizziness

5.6 Dizziness CYKLOKAPRON may cause dizziness. Concomitant use of other drugs that may also cause dizziness may worsen this effect. Advise patients to avoid driving or using machines until they know how CYKLOKAPRON affects them.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Prothrombotic Medical Products: Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid. (5.2, 7.1, 8.3) 7.1 Prothrombotic Medical Products Avoid concomitant use of CYKLOKAPRON with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.2), Use in Specific Populations (8.3)].

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Risk of Medication Errors Due to Incorrect Route of Administration [see Warnings and Precautions (5.1)]
  • Thromboembolic Risk [see Warnings and Precautions (5.2)]
  • Seizures [see Warnings and Precautions (5.3)]
  • Hypersensitivity Reactions [see Warnings and Precautions (5.4)]
  • Visual Disturbances [see Warnings and Precautions (5.5)]
  • Dizziness [see Warnings and Precautions (5.6)] Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of tranexamic acid. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur and may resolve with dose-reduction. Allergic dermatitis and giddiness have been reported. Hypotension has been reported when intravenous injection is too rapid. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery, vein obstruction and cases associated with concomitant use of combination hormonal contraceptives) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia. Convulsion, chromatopsia, and visual impairment have also been reported. Anaphylaxis or anaphylactoid reactions have been reported that are suggestive of a causal relationship.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. There are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear.

Tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration (see Data). Reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on the fetus due to tranexamic acid administered during organogenesis. Doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) the maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively (see Data).

The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2–4% and 15–20%, respectively.

It is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. For decisions regarding the use of CYKLOKAPRON during pregnancy, the potential risk of CYKLOKAPRON administration on the fetus should always be considered along with the mother's clinical need for CYKLOKAPRON; an accurate risk-benefit evaluation should drive the treating physician's decision.

Data Human Data Tranexamic acid passes through the placenta. The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in the maternal blood. There were 13 clinical studies that described fetal and/or neonatal functional issues such as low Apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22–36 weeks of gestation in fetuses and infants exposed to tranexamic acid in-utero.

Animal Data In embryo-fetal development studies, tranexamic acid was administered to pregnant mice from Gestation Day (GD) 6 through GD 12 and rats from GD 9 through GD 14 at daily doses of 0.3 or 1.5 g/kg. There was no evidence of adverse developmental outcomes in mice and rats at multiple of 3 and 6 times the maximum recommended human dose based on body surface area in the mouse and rat, respectively.

In rabbits, tranexamic acid was administered intravenously at doses of 50, 100, or 200 mg/kg/day or orally at doses of 100, 200, or 400 mg/kg/day from GD 6 through GD 18. There was no evidence of adverse developmental outcomes at dose multiples of 2 or 3 times, respectively, the maximum recommended human dose based on body surface area.

Intravenous doses of 200 mg/kg/day showed slightly retarded weight gain in pregnant rabbits.

Mechanism of action

12.1 Mechanism of Action Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin's matrix structure.

The antifibrinolytic effects of tranexamic acid are mediated by reversible interactions at multiple binding sites within plasminogen. Native human plasminogen contains 4 to 5 lysine binding sites with low affinity for tranexamic acid (Kd = 750 μmol/L) and 1 with high affinity (Kd = 1.1 μmol/L). The high affinity lysine site of plasminogen is involved in its binding to fibrin.

Saturation of the high affinity binding site with tranexamic acid displaces plasminogen from the surface of fibrin. Although plasmin may be formed by conformational changes in plasminogen, binding to and dissolution of the fibrin matrix is inhibited.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Tranexamic acid, in concentrations of 1 mg/mL and 10 mg/mL prolongs the thrombin time. An antifibrinolytic concentration of tranexamic acid remains in different tissues for about 17 hours, and in the serum, up to 7 or 8 hours. Tranexamic acid in concentrations up to 10 mg/mL blood has no influence on the platelet count, the coagulation time or various coagulation factors in whole blood or citrated blood from healthy subjects.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination After an intravenous dose of 1 g, the plasma concentration time curve shows a triexponential decay with a half-life of about 2 hours for the terminal elimination phase.

Excretion Urinary excretion is the main route of elimination via glomerular filtration.

Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug.

Excretion of tranexamic acid is about 90% at 24 hours after intravenous administration of 10 mg/kg body weight.

Urinary excretion following a single intravenous injection of tranexamic acid declines as renal function decreases.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Distribution The initial volume of distribution is about 9 to 12 liters. The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin. Elimination After an intravenous dose of 1 g, the plasma concentration time curve shows a triexponential decay with a half-life of about 2 hours for the terminal elimination phase.

Excretion Urinary excretion is the main route of elimination via glomerular filtration. Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug. Excretion of tranexamic acid is about 90% at 24 hours after intravenous administration of 10 mg/kg body weight.

Specific Populations Patients with Renal Impairment The blood levels of tranexamic acid are increased in patients with renal insufficiency. Urinary excretion following a single intravenous injection of tranexamic acid declines as renal function decreases. Following a single 10 mg/kg intravenous injection of tranexamic acid, the 24-hour urinary fractions of tranexamic acid with serum creatinine concentrations 1.4 – 2.8, 2.8 – 5.7, and greater than 5.7 mg/dL were 51, 39, and 19%, respectively.

The 24-hour tranexamic acid plasma concentrations for these patients demonstrated a direct relationship to the degree of renal impairment. Therefore, dose adjustment is needed in patients with renal impairment [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Drug Interaction Studies No studies of interactions between CYKLOKAPRON and other drugs have been conducted.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Tranexamic Acid 100 mg/mL, 5 mL Ampule₱12.22–₱950.00Reference ₱14.32per ampuleDPRI procurement range
Tranexamic Acid 500 mg Capsule₱3.48–₱15.00Reference ₱5.38per capsuleDPRI procurement range
Tranexamic Acid 500 mg Tablet₱5.00–₱5.90Reference ₱5.63per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Tranexamic Acid
PNF listingOral: 250 mg and 500 mg capsule 500 mg tablet
PNF listingInj.: 100 mg/mL, 2.5 mL and 5 mL ampul (IM, IV)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Cyklokapron · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 34, September 3, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e89a7d9-4da4-42aa-b7f8-c602c24eefe5
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .